| 000 | 01792 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517215400.0 | ||
| 264 | 0 | _c20190403 | |
| 008 | 201904s 0 0 eng d | ||
| 022 | _a1745-7254 | ||
| 024 | 7 |
_a10.1038/s41401-018-0020-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGao, Ming-Zhao | |
| 245 | 0 | 0 |
_aAberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. _h[electronic resource] |
| 260 |
_bActa pharmacologica Sinica _cFeb 2019 |
||
| 300 |
_a268-278 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xpharmacology |
| 650 | 0 | 4 |
_aMAP Kinase Signaling System _xdrug effects |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aOximes _xpharmacology |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins B-raf _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyridones _xpharmacology |
| 650 | 0 | 4 |
_aPyrimidinones _xpharmacology |
| 650 | 0 | 4 |
_aRibosomal Protein S6 _xmetabolism |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 700 | 1 | _aWang, Hong-Bin | |
| 700 | 1 | _aChen, Xiang-Ling | |
| 700 | 1 | _aCao, Wen-Ting | |
| 700 | 1 | _aFu, Li | |
| 700 | 1 | _aLi, Yun | |
| 700 | 1 | _aQuan, Hai-Tian | |
| 700 | 1 | _aXie, Cheng-Ying | |
| 700 | 1 | _aLou, Li-Guang | |
| 773 | 0 |
_tActa pharmacologica Sinica _gvol. 40 _gno. 2 _gp. 268-278 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41401-018-0020-z _zAvailable from publisher's website |
| 999 |
_c28406823 _d28406823 |
||